Document Detail

Romidepsin for the treatment of cutaneous T-cell lymphoma.
MedLine Citation:
PMID:  20126671     Owner:  NLM     Status:  MEDLINE    
Aberrant epigenetic gene regulation by deacetylation of histone proteins has been involved in tumorigenesis. Histone deacetilase (HDAC) inhibitors are promising anticancer agents under research and development. Romidepsin is a novel and potent HDAC inhibitor highly efficient in inhibiting HDAC activity even at nanomolar concentrations. It exhibits a considerably stronger direct inhibition in class I HDAC enzymes as compared to class II. In addition of histone deacetylation, romidepsin modulates additional targets involved in cancer initiation and progression such as c-myc, Hsp90 and p53. Romidepsin has shown promising anticancer effects in a wide variety of nonclinical cancer models both in vitro and in vivo by induction of apoptosis, cell differentiation and cell cycle arrest. Romidepsin has been recently approved by the FDA for the treatment of cutaneous T-cell lymphoma (CTCL) patients who have received at least one prior systemic therapy. It is currently under clinical investigation for the treatment of other hematological malignances and solid tumors as monotherapy and in combination with other anticancer agents.
Clara Campas-Moya
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Drugs of today (Barcelona, Spain : 1998)     Volume:  45     ISSN:  1699-3993     ISO Abbreviation:  Drugs Today     Publication Date:  2009 Nov 
Date Detail:
Created Date:  2010-02-03     Completed Date:  2010-04-27     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101160518     Medline TA:  Drugs Today (Barc)     Country:  Spain    
Other Details:
Languages:  eng     Pagination:  787-95     Citation Subset:  IM    
Copyright Information:
Copyright 2009 Prous Science, S.A.U. or its licensors. All rights reserved.
ADVANCELL Advanced In Vitro Cell Technologies, S.A, Barcelona, Spain.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antibiotics, Antineoplastic / adverse effects,  pharmacology,  therapeutic use*
Clinical Trials as Topic
Depsipeptides / adverse effects,  pharmacology,  therapeutic use*
Drug Evaluation, Preclinical
Drug Resistance, Neoplasm
Lymphoma, T-Cell, Cutaneous / drug therapy*,  physiopathology
Reg. No./Substance:
0/Antibiotics, Antineoplastic; 0/Depsipeptides; 128517-07-7/romidepsin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Ferumoxytol for the treatment of anemia in chronic kidney disease.
Next Document:  Pixantrone maleate for non-Hodgkin's lymphoma.